Who Pays My Doctor?

Healthcare provider profile · identity verified

Ilan Melnick, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · CORAL GABLES, FL · NPI 1427048115

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ilan Melnick, M.D. received $813,000.13 in general payments during 2025 across 745 reported records.

Neurocrine BioSciences, Inc. accounted for 19.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 20 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Austedo Xr, Caplyta, Rexulti, Trintellix, Uzedy.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aristada by this doctor in 2024.

H. Lundbeck A S reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 50 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo Xr by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Uzedy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$813,000.13

745 reported records · 20 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $160,072.7919.7%1452025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $141,765.7817.4%1162025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $139,943.7117.2%1332025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $119,505.8414.7%942025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $88,698.8810.9%702025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $70,830.038.7%802025
ABBVIE INC. Unresolved — no canonical attribution shown $21,853.152.7%242025
H. Lundbeck A S Unresolved — no canonical attribution shown $21,194.002.6%132025
Alkermes, Inc. Unresolved — no canonical attribution shown $16,436.082.0%232025
Boehringer Ingelheim International GmbH Unresolved — no canonical attribution shown $11,748.331.4%12025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $10,347.281.3%132025
Luye Pharma (USA) Ltd. Unresolved — no canonical attribution shown $6,158.060.8%82025
Otsuka Pharmaceutical Development & Commercialization, Inc. Unresolved — no canonical attribution shown $3,795.170.5%52025
Lundbeck LLC Unresolved — no canonical attribution shown $236.370.0%102025
Noven Therapeutics, LLC Unresolved — no canonical attribution shown $137.500.0%12025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $98.750.0%12025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $80.550.0%42025
Biogen, Inc. Unresolved — no canonical attribution shown $51.870.0%22025
Tris Pharma Inc Unresolved — no canonical attribution shown $24.070.0%12025
IDORSIA PHARMACEUTICALS US INC Unresolved — no canonical attribution shown $21.920.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$487,927.00135
Consulting Fee$130,434.0839
Travel and Lodging$103,492.79266
Honoraria$73,456.5021
Food and Beverage$17,580.27283
Education$109.491

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $160,072.79 145 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $103,754.28 87 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $88,698.88 70 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug H. Lundbeck A S, Otsuka America Pharmaceutical, Inc. $80,681.78 74 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. $80,570.26 74 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $70,802.71 79 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $63,772.37 42 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. $59,500.24 72 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $53,386.31 49 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $21,853.15 24 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $16,436.08 23 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $10,347.28 13 2025
Source payment records
ERZOFRI EXTENDED-RELEASE
Normalized: erzofri extended release		 Drug Luye Pharma (USA) Ltd. $6,158.06 8 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $493.17 9 2025
Source payment records
Xelstrym
Normalized: xelstrym		 Drug Noven Therapeutics, LLC $137.50 1 2025
Source payment records
TRINTELLIX
Normalized: trintellix		 Drug Takeda Pharmaceuticals U.S.A., Inc. $80.55 4 2025
Source payment records
ZURZUVAE
Normalized: zurzuvae		 Drug Biogen, Inc. $51.87 2 2025
Source payment records
Symbravo
Normalized: symbravo		 Drug Axsome Therapeutics, Inc. $27.32 1 2025
Source payment records
Dyanavel XR
Normalized: dyanavel xr		 Drug Tris Pharma Inc $24.07 1 2025
Source payment records
Quviviq
Normalized: quviviq		 Drug IDORSIA PHARMACEUTICALS US INC $21.92 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
ARISTADA
aristada		 2025 Aristada 2024 13
Beneficiary count suppressed		 exact normalized Medicare Part D
AUSTEDO XR
austedo xr		 2025 Austedo Xr 2024 18
Beneficiary count suppressed		 exact normalized Medicare Part D
CAPLYTA
caplyta		 2025 Caplyta 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
REXULTI
rexulti		 2025 Rexulti 2024 31
Beneficiary count suppressed		 exact normalized Medicare Part D
TRINTELLIX
trintellix		 2025 Trintellix 2024 58
Beneficiary count suppressed		 exact normalized Medicare Part D
UZEDY
uzedy		 2025 Uzedy 2024 57
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Alkermes, Inc.
Exact reporting entity; no affiliate inference		 2025 ARISTADA
open payments reported associated product		 CMS Open Payments — General Payments
76041 supporting records · 17486 recipient NPIs · example record 1222428566 		Aristada · 2024
Exact normalized brand match · 1 Part D row		 13 suppressed by CMS
H. Lundbeck A S
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
50 supporting records · 15 recipient NPIs · example record 1251761642 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 31 suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Exact reporting entity; no affiliate inference		 2025 CAPLYTA
open payments reported associated product		 CMS Open Payments — General Payments
211855 supporting records · 46143 recipient NPIs · example record 1241243071 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Lundbeck LLC
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
71829 supporting records · 25812 recipient NPIs · example record 1251759986 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 31 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
160756 supporting records · 46288 recipient NPIs · example record 1227267708 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 31 suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
1463 supporting records · 1088 recipient NPIs · example record 1225319865 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 31 suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc.
Exact reporting entity; no affiliate inference		 2025 TRINTELLIX
open payments reported associated product		 CMS Open Payments — General Payments
37075 supporting records · 14402 recipient NPIs · example record 1223616266 		Trintellix · 2024
Exact normalized brand match · 1 Part D row		 58 suppressed by CMS
Teva Pharmaceuticals USA, Inc.
Exact reporting entity; no affiliate inference		 2025 AUSTEDO XR
open payments reported associated product		 CMS Open Payments — General Payments
86263 supporting records · 23643 recipient NPIs · example record 1247244228 		Austedo Xr · 2024
Exact normalized brand match · 1 Part D row		 18 suppressed by CMS
Teva Pharmaceuticals USA, Inc.
Exact reporting entity; no affiliate inference		 2025 UZEDY
open payments reported associated product		 CMS Open Payments — General Payments
46702 supporting records · 13355 recipient NPIs · example record 1247244226 		Uzedy · 2024
Exact normalized brand match · 1 Part D row		 57 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
OlanzapineOlanzapine107suppressed
Benztropine MesylateBenztropine Mesylate84suppressed
Divalproex Sodium ErDivalproex Sodium76suppressed
ClonazepamClonazepam7411
Trazodone HclTrazodone Hcl6912
Quetiapine FumarateQuetiapine Fumarate68suppressed
RisperidoneRisperidone66suppressed
TrintellixVortioxetine Hydrobromide58suppressed
UzedyRisperidone57suppressed
LorazepamLorazepam51suppressed
Olanzapine OdtOlanzapine48suppressed
Chlorpromazine HclChlorpromazine Hcl47suppressed
Quetiapine Fumarate ErQuetiapine Fumarate47suppressed
Citalopram HbrCitalopram Hydrobromide41suppressed
GabapentinGabapentin39suppressed
Doxepin HclDoxepin Hcl36suppressed
Fluphenazine HclFluphenazine Hcl36suppressed
Trihexyphenidyl HclTrihexyphenidyl Hcl36suppressed
AlprazolamAlprazolam35suppressed
HaloperidolHaloperidol31suppressed
OzempicSemaglutide31suppressed
RexultiBrexpiprazole31suppressed
DiazepamDiazepam29suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27suppressed
Invega SustennaPaliperidone Palmitate26suppressed
Divalproex SodiumDivalproex Sodium24suppressed
Sertraline HclSertraline Hcl24suppressed
Duloxetine HclDuloxetine Hcl23suppressed
Fluoxetine HclFluoxetine Hcl22suppressed
Lurasidone HclLurasidone Hcl22suppressed
Zolpidem TartrateZolpidem Tartrate21suppressed
Bupropion XlBupropion Hcl20suppressed
ClozapineClozapine19suppressed
Austedo XrDeutetrabenazine18suppressed
LamotrigineLamotrigine18suppressed
SeroquelQuetiapine Fumarate17suppressed
DayvigoLemborexant14suppressed
EszopicloneEszopiclone14suppressed
Levothyroxine SodiumLevothyroxine Sodium14suppressed
AristadaAripiprazole Lauroxil13suppressed
EmsamSelegiline13suppressed
Haloperidol DecanoateHaloperidol Decanoate13suppressed
Asenapine MaleateAsenapine Maleate12suppressed
CaplytaLumateperone Tosylate12suppressed
Lamotrigine OdtLamotrigine12suppressed
PerphenazinePerphenazine11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $813,000.13 · 745 records Neurocrine BioSciences, Inc. ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, Dyanavel XR, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, LYBALVI, Quviviq, REXULTI, Symbravo, TRINTELLIX, UZEDY, VRAYLAR, Xelstrym, ZURZUVAE 9 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error